10−6chr16:73501786Ripke et al., 2013bAustralia/Europe/U.S.Discovery9,2409,5191,235,109RMD/MDrs115799640.8461.00 × 10−7chr1:224538690Australia/Europe/U.S.Replication6,78350,695––rs19692531.0494.79 × 10−6chr3:183876262Kohli et al., 2011Europe/U.S.Discovery353366365,676MD/RMDrs15458432.845.53 × 10−8chr12:84563818Europe/U.S.Replication3,73810,635––rs15458431.3151.40 × 10−9chr12:84563818Rietschel et al., 2010GermanDiscovery6041,364491,238MDrs27654931.452.26 × 10−7chr1:157797750GermanMeta1,0131,905––rs77139170.751.48 × 10−6chr5:78828999This table gives the number of cases and controls for each GWAS and summarizes results. The sample sizes listed are those used in the discovery phase, replication, and meta-analyses (meta). The number of SNPs given is that used in the association analysis, which in some cases (Wray et al., 2012, Ripke et al., 2013b) includes imputed data. The highest scoring markers are listed for each study, with their odds ratio (OR) and chromosomal location. Studies used different inclusion criteria; these are summarized under the column headed phenotype, in which “RMD” is recurrent major depression and “MD” is major depression. Where provided, the numbers of each phenotypic category are listed.
